Interneuron, Les Laboratoires Servier, Wyeth-Ayerst sales and marketing update

Wyeth-Ayerst withdrew its Pondimin fenfluramine and IPIC's Redux dexfenfluramine from the market in the U.S. after the FDA released new data regarding possible heart valve defects associated with use of the drugs (see BioCentury Extra, Sept. 16). Redux, licensed to IPIC in the U.S. by Servier, was sublicensed to Wyeth-Ayerst by IPIC. Servier withdrew both dexfenfluramine from the market in Europe as well. ...